Alessandro Blasimme
Dados Biográficos
| ID | 2744360 |
|---|---|
| NOME | Alessandro Blasimme |
| PRENOMES | Alessandro |
| SOBRENOME | Blasimme |
| ASSINATURA | BLASIMME A |
| AFILIAÇÕES | ETH Zurich |
| ORCID | 0000-0001-5908-2002 |
| VERIFICADO | Sim |
| TOTAL DE OBRAS | 16 |
| TOTAL DE CITAÇÕES | 8 |
| TOTAL COMO AUTOR | 16 |
| TOTAL COMO EDITOR | 0 |
| PRIMEIRO ANO DE PUBLICAÇÃO | 2011 |
| ANO MAIS RECENTE DE PUBLICAÇÃO | 2025 |
| ÍNDICE H | 2 |
Disentangling Responsibility
Dementia prevention has become a priority in medical research and public health. Various medical, social and environmental risk factors have been identified; however, medical studies, media discourses and health policies predominantly centre on individual‐level prevention and promote personal responsibility for maintaining cognitive health. This emphasis on individual preventive efforts faces increasing criticism for being ethically problematic, …
Can digital tools foster ethical deliberation
In the age of Machine Learning Algorithms, Artificial Intelligence and Natural Language Processing, digital technologies have become interwoven in various aspects of society, including in our practices for ethical deliberation and decision-making. In this study, we present a systematic mapping and taxonomy of digital tools designed explicitly for this purpose and published between 2010 and 2023. By providing a comprehensive overview of the landsc…
Talking Ethics Early in Health Data Public Private Partnerships
Data access and data sharing are vital to advance medicine. A growing number of public private partnerships are set up to facilitate data access and sharing, as private and public actors possess highly complementary health data sets and treatment development resources. However, the priorities and incentives of public and private organizations are frequently in conflict. This has complicated partnerships and sparked public concerns around ethical …
Digital bioethics
The online space has become a digital public square, where individuals interact and share ideas on the most trivial to the most serious of matters, including discussions of controversial ethical issues in science, technology and medicine. In the last decade, new disciplines like computational social science and social data science have created methods to collect and analyse such data that have considerably expanded the scope of social science res…
Accelerated drug approval
Drugs addressing unmet medical needs can change the lives of millions. Developing and validating new drugs can, however, take many years. To streamline the assessment of new drugs, regulatory agencies have long established shortened review pathways. Among these programs, Accelerated Approval (AA) has recently come under scrutiny due to the U.S. Food and Drug Administration's decision to authorize Aducanumab, the first Alzheimer's disease drug. Th…
The translational lag narrative in policy discourse in the United States and the European Union
Whilst basic science rapidly produces new insights into the biological determinants of human health and disease, clinical innovation is often said to lag behind, as it fails to rapidly turn such knowledge into new tools for innovative patient care. This view of biomedical innovation constitutes a ‘translational lag narrative’, which is widely present in current research policy. This paper presents a qualitative content analysis of a corpus of doc…
Rethinking ageing
The plasticity of ageing and the rediscovery of ground-state prevention
In this paper, I present an emerging explanatory framework about ageing and care. In particular, I focus on how, in contrast to most classical accounts of ageing, biomedicine today construes the ageing process as a modifiable trajectory. This framing turns ageing from a stage of inexorable decline into the focus of preventive strategies, harnessing the functional plasticity of the ageing organism. I illustrate this shift by focusing on studies of…
Explainability for artificial intelligence in healthcare
Why Include the Public in Genome Editing Governance Deliberation
With the birth of genetically engineered twins in November 2018, international debate about human genome editing governance has moved from an emphasis on mutual engagement among multiple stakeholders to a self-regulatory model enacted through high-level expert groups with little or no public input. This article reconstructs this paradigm shift and suggests that inclusive public deliberation should still have a role in public decision making about…
Ethics, Values, and Responsibility in Human Genome Editing
CRISPR/Cas9 genome editing is an inexpensive and efficient tool to introduce changes in DNA. Its ease of use sets virtually no limits on potential scientific and clinical applications. Prospects include correcting congenital monogenic disorders, targeting disease-causing molecular lesions, 1 and even altering multiple genetic loci at the same time. 2 Beyond therapeutic applications, there is at least in principle the possibility that CRISPR/Cas9 …
Big Data, precision medicine and private insurance
In this paper, we discuss how access to health-related data by private insurers, other than affecting the interests of prospective policy-holders, can also influence their propensity to make personal data available for research purposes. We take the case of national precision medicine initiatives as an illustrative example of this possible tendency. Precision medicine pools together unprecedented amounts of genetic as well as phenotypic data. The…
Machine learning in medicine
A recent United Kingdom survey reports that 63% of the adult population is uncomfortable with allowing personal data to be used to improve healthcare and is unfavorable to artificial intelligence (AI) systems replacing doctors and nurses in tasks they usually perform Another study, conducted in Germany, found that medical students-the doctors of tomorrow-overwhelmingly buy into the promise of AI to improve medicine (83%) but are more skeptical th…
Democratizing Health Research Through Data Cooperatives
Massive amounts of data are collected and stored on a routine basis in virtually all domains of human activities. Such data are potentially useful to biomedicine. Yet, access to data for research purposes is hindered by the fact that different kinds of individual-patient data reside in disparate, unlinked silos. We propose that data cooperatives can promote much needed data aggregation and consequently accelerate research and its clinical transla…
What mechanisms can’t do
Governare la biomedicina
L'articolo prende in esame i problemi etici connessi con le scienze della vita e i modelli di decisione pubblica messi in atto per fare fronte al crescente disaccordo morale sui metodi e gli scopi della ricerca. Mostra inoltre come negli ultimi decenni si siano affermati modelli di della scienza improntati a visioni differenti dei rapporti tra comunitŕ scientifica, comunitŕ bioetica e decisori pubblici. Fornisce infine un'analisi dei fondamenti t…
Big Data, precision medicine and private insurance
In this paper, we discuss how access to health-related data by private insurers, other than affecting the interests of prospective policy-holders, can also influence their propensity to make personal data available for research purposes. We take the case of national precision medicine initiatives as an illustrative example of this possible tendency. Precision medicine pools together unprecedented amounts of genetic as well as phenotypic data. The…
The plasticity of ageing and the rediscovery of ground-state prevention
In this paper, I present an emerging explanatory framework about ageing and care. In particular, I focus on how, in contrast to most classical accounts of ageing, biomedicine today construes the ageing process as a modifiable trajectory. This framing turns ageing from a stage of inexorable decline into the focus of preventive strategies, harnessing the functional plasticity of the ageing organism. I illustrate this shift by focusing on studies of…
What mechanisms can’t do
Governare la biomedicina
L'articolo prende in esame i problemi etici connessi con le scienze della vita e i modelli di decisione pubblica messi in atto per fare fronte al crescente disaccordo morale sui metodi e gli scopi della ricerca. Mostra inoltre come negli ultimi decenni si siano affermati modelli di della scienza improntati a visioni differenti dei rapporti tra comunitŕ scientifica, comunitŕ bioetica e decisori pubblici. Fornisce infine un'analisi dei fondamenti t…
What mechanisms can’t do
Machine learning in medicine
A recent United Kingdom survey reports that 63% of the adult population is uncomfortable with allowing personal data to be used to improve healthcare and is unfavorable to artificial intelligence (AI) systems replacing doctors and nurses in tasks they usually perform Another study, conducted in Germany, found that medical students-the doctors of tomorrow-overwhelmingly buy into the promise of AI to improve medicine (83%) but are more skeptical th…
Democratizing Health Research Through Data Cooperatives
Massive amounts of data are collected and stored on a routine basis in virtually all domains of human activities. Such data are potentially useful to biomedicine. Yet, access to data for research purposes is hindered by the fact that different kinds of individual-patient data reside in disparate, unlinked silos. We propose that data cooperatives can promote much needed data aggregation and consequently accelerate research and its clinical transla…
Why Include the Public in Genome Editing Governance Deliberation
With the birth of genetically engineered twins in November 2018, international debate about human genome editing governance has moved from an emphasis on mutual engagement among multiple stakeholders to a self-regulatory model enacted through high-level expert groups with little or no public input. This article reconstructs this paradigm shift and suggests that inclusive public deliberation should still have a role in public decision making about…
Ethics, Values, and Responsibility in Human Genome Editing
CRISPR/Cas9 genome editing is an inexpensive and efficient tool to introduce changes in DNA. Its ease of use sets virtually no limits on potential scientific and clinical applications. Prospects include correcting congenital monogenic disorders, targeting disease-causing molecular lesions, 1 and even altering multiple genetic loci at the same time. 2 Beyond therapeutic applications, there is at least in principle the possibility that CRISPR/Cas9 …
Big Data, precision medicine and private insurance
In this paper, we discuss how access to health-related data by private insurers, other than affecting the interests of prospective policy-holders, can also influence their propensity to make personal data available for research purposes. We take the case of national precision medicine initiatives as an illustrative example of this possible tendency. Precision medicine pools together unprecedented amounts of genetic as well as phenotypic data. The…
Explainability for artificial intelligence in healthcare
The translational lag narrative in policy discourse in the United States and the European Union
Whilst basic science rapidly produces new insights into the biological determinants of human health and disease, clinical innovation is often said to lag behind, as it fails to rapidly turn such knowledge into new tools for innovative patient care. This view of biomedical innovation constitutes a ‘translational lag narrative’, which is widely present in current research policy. This paper presents a qualitative content analysis of a corpus of doc…
Rethinking ageing
The plasticity of ageing and the rediscovery of ground-state prevention
In this paper, I present an emerging explanatory framework about ageing and care. In particular, I focus on how, in contrast to most classical accounts of ageing, biomedicine today construes the ageing process as a modifiable trajectory. This framing turns ageing from a stage of inexorable decline into the focus of preventive strategies, harnessing the functional plasticity of the ageing organism. I illustrate this shift by focusing on studies of…
Digital bioethics
The online space has become a digital public square, where individuals interact and share ideas on the most trivial to the most serious of matters, including discussions of controversial ethical issues in science, technology and medicine. In the last decade, new disciplines like computational social science and social data science have created methods to collect and analyse such data that have considerably expanded the scope of social science res…
Accelerated drug approval
Drugs addressing unmet medical needs can change the lives of millions. Developing and validating new drugs can, however, take many years. To streamline the assessment of new drugs, regulatory agencies have long established shortened review pathways. Among these programs, Accelerated Approval (AA) has recently come under scrutiny due to the U.S. Food and Drug Administration's decision to authorize Aducanumab, the first Alzheimer's disease drug. Th…
Can digital tools foster ethical deliberation
In the age of Machine Learning Algorithms, Artificial Intelligence and Natural Language Processing, digital technologies have become interwoven in various aspects of society, including in our practices for ethical deliberation and decision-making. In this study, we present a systematic mapping and taxonomy of digital tools designed explicitly for this purpose and published between 2010 and 2023. By providing a comprehensive overview of the landsc…
Talking Ethics Early in Health Data Public Private Partnerships
Data access and data sharing are vital to advance medicine. A growing number of public private partnerships are set up to facilitate data access and sharing, as private and public actors possess highly complementary health data sets and treatment development resources. However, the priorities and incentives of public and private organizations are frequently in conflict. This has complicated partnerships and sparked public concerns around ethical …
Disentangling Responsibility
Dementia prevention has become a priority in medical research and public health. Various medical, social and environmental risk factors have been identified; however, medical studies, media discourses and health policies predominantly centre on individual‐level prevention and promote personal responsibility for maintaining cognitive health. This emphasis on individual preventive efforts faces increasing criticism for being ethically problematic, …
Political science (12 obras) · Computer Science (8 obras) · Medicine (8 obras) · Engineering ethics (7 obras) · Biomedical Ethics and Regulation (6 obras) · Data science (6 obras) · Engineering (6 obras) · Biology (5 obras) · Ethics in Clinical Research (5 obras) · Law (5 obras)